Skip to main content
Fig. 2 | Biology Direct

Fig. 2

From: Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number

Fig. 2

The procedures used in the clinical trial treating castration-resistant prostate cancer (CRPC) [12]. Biopsy samples of the prostate were taken and a suspension of tumour cells (TC) was produced in the GMP facility. Monocytes were harvested from the same patient by leukapheresis to produce dendritic cells (DC) in the lab. These were then electrofused with TCs to obtain immunohybridomas, aHyC, which were applied subcutaneously into the patient four times

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us